High Intensity Contact Ultrasound Interstitial Medical Device

A new vision of surgery

“Surgery is undergoing rapid changes. Vascular diseases are now treated using endovascular techniques and extravascular pathologies are now treated using endoscopic and robotic techniques. This represents a significant change for the surgeon, who has the desire to minimize the aggressiveness of his actions. However, in the near future, these endoscopic and robotic techniques should give way to pure percutaneous techniques. Soon surgery will no longer be “open, sleep, pain and hospitalization,” but rather “diagnose, phenotype, coagulate, resect” and this will be done safely because all procedures will be performed under continuous image monitoring. This is the surgery of tomorrow. This change may seem impossible. Yet it is possible.” Pr Carpentier

This is the goal of the research performed by CarThera: develop a totally new medical technology that can be performed in a single outpatient procedure, under local anesthesia and using real-time MRI monitoring.

Between 2006 and 2009, Pr. Alexandre Carpentier, in collaboration with an American team, performed two clinical trials using a probe that emits laser energy to destroy brain tumors under real-time MRI control (A. Carpentier et al., Journal of Neurosurgery 2008; A. Carpentier et al., Lasers in Surgery and Medicine, 2011; A. Carpentier et al., Lasers in Surgery and Medicine, 2012). 

le monde couverture paint2

This first human trial allowed CarThera® to highlight the benefits of the use of MRI as an interventional tool and significantly increased patient survival (+12.8 months). But, several limitations were also noted: it was difficult to use the laser probe for treating complex tumor shapes; histological diagnosis during the procedure was not possible; and, it was not possible to extract necrotic tissue after the procedure, which created an undesirable mass effect after treatments.






The SonoProbe

At CarThera, we wanted to solve those three issues by developing a new probe that contains two major innovations:

(i) changing the energy source for inducing heating of tissue from a laser to ultrasound to allow for a better adaptation of the thermal treatment to the tumor shape without having to move the probe.

(ii) adding a central canal to the device to allow the surgeon to perform biopsies at the beginning of the treatment and to perform tissue removal at the end of the treatment to decrease the mass effect.

This is how the SonoProbe program was born.


  • unnamed-2

  • News CarThera

    May 2018 – CarThera will participate to BIO 2018 in Boston

    CarThera will participate to the BIO International Convention in Boston on June 4-7 to meet with global biotech and pharma leaders and showcase its SonoCloud device.

    Should you want to meet us at BIO and hear more about SonoCloud – our ultrasound device, aimed at improving treatment efficiency by temporarily opening the Blood Brain Barrier – contact us at and come to Booth 527 at the France Pavilion.

    CarThera presented data from phase 1/2a study at 2017 ASCO annual meeting

    June 2017 – Dr. Ahmed Idbaih, AP-HP principal investigator of the Phase 1/2a clinical trial (NCT02253212) on ultrasound induced Blood-Brain Barrier opening revealed preliminary safety and efficacy data at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

    The clinical data from the trial involving 21 patients with recurrent glioblastoma, who have all been treated with SonoCloud® low-intensity pulsed ultrasound in a total of 65 sessions, have been shared with more than 30,000 oncology professionals from around the world.

    CarThera secures €5.7 million in funding for its DOME project

    October 12, 2016 – CarThera has received a grant of €5.7 million ($6.4m) for its DOME project. The funding was awarded under the call for proposals ‘Structuring R&D Projects for Competitiveness’ from France’s ‘Investments for the Future Program’, led by the General Investment Commission and run by Bpifrance.

    The grant will finance our SonoCloud Phase 2b/3 study in glioblastoma that will involve around 200 patients at centers in Europe and the United States. It will also fund a number of exploratory studies, including one on Alzheimer’s disease, building on the findings from the Phase 1/2a study that paved the way for a broader array of clinical indications.